High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28523155)

Published in J Thorac Dis on April 01, 2017

Authors

Xueli Yang1,2, Zhengquan Zhang3, Xiaoqing Jia2, Yanqin Zhang1, Tianyang Mu1, Bingzheng Zhou1, Lin Li1, Deyuan Fu3, Xin Hu2, Shunbin Xiong1,4

Author Affiliations

1: Department of Cancer Stem Cell, Dalian Medical University, Dalian 116000, China.
2: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200030, China.
3: Department of Thyroid and Breast Surgery, Northern Jiangsu People's Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, China.
4: Department of Genetics, M.D. Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA.

Articles cited by this

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29

Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16

The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer (2003) 6.70

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med (2010) 6.04

Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell (2010) 5.47

PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81

Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77

The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev (2010) 1.47

Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. J Cell Biol (1997) 1.45

Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). J Biol Chem (2008) 1.42

Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene (1994) 1.42

Molecular pathways: HER3 targeted therapy. Clin Cancer Res (2014) 1.41

Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12. Oncogene (1998) 1.10

Partial reversion of the transformed phenotype in HRAS-transfected tumorigenic cells by transfer of a human gene. Proc Natl Acad Sci U S A (1988) 1.10

Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells. J Cell Sci (2007) 1.05

The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells. Oncogene (2002) 0.95

H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling. Am J Pathol (2006) 0.93

PLA2G16 Expression in Human Osteosarcoma Is Associated with Pulmonary Metastasis and Poor Prognosis. PLoS One (2015) 0.88

hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors. Oncogene (2001) 0.86

H-rev107 regulates prostaglandin D2 synthase-mediated suppression of cellular invasion in testicular cancer cells. J Biomed Sci (2013) 0.86

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway. Oncotarget (2016) 0.84

Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. Drug Resist Updat (2015) 0.82

Phospholipase A/Acyltransferase enzyme activity of H-rev107 inhibits the H-RAS signaling pathway. J Biomed Sci (2014) 0.81